Dr. Akwo brings a unique blend of regulatory, field, and analytical expertise, informed by his experience as an Assistant Public Health Inspector in Ontario, where he led communicable disease investigations, outbreak response, environmental health inspections, and enforcement of public health legislation. This frontline perspective underpins his work in designing responsive and integrated surveillance systems.

 

His expertise in pharmacoepidemiology and drug safety surveillance focuses on monitoring and evaluating medications used for the treatment and prevention of infectious diseases, including antimicrobial therapies, vaccines, and biologics. He has contributed to strengthening pharmacovigilance systems by supporting adverse drug reaction (ADR) detection, reporting, and signal assessment, with particular attention to drug safety in the context of co-infections, antimicrobial resistance, and complex treatment regimens. His work also extends to safety monitoring of therapies related to allergy and immunological responses, as well as infection-associated oncological conditions, where immune-mediated and long-term treatment effects require robust surveillance.

 

Dr. Akwo has advised Ministries of Health and public health institutions on integrating pharmacovigilance into broader surveillance frameworks, linking clinical, laboratory, and population-level data to improve early signal detection and risk management. He has supervised research on pharmacovigilance systems and healthcare worker reporting behaviors and applies advanced epidemiological methods and AI-supported analytics to enhance data quality, interoperability, and predictive capacity.

 

At Vigiquest Analytics, Dr. Akwo supports the design and optimization of pharmacovigilance and product safety systems, capacity building for healthcare professionals, and the development of evidence-based strategies to strengthen product safety monitoring and regulatory compliance across diverse health system contexts.